LLY

885.52

+0.86%↑

JNJ

242.36

+0.87%↑

ABBV

213.25

+1.7%↑

NVS

150.37

+1.43%↑

MRK

117.85

-1.53%↓

LLY

885.52

+0.86%↑

JNJ

242.36

+0.87%↑

ABBV

213.25

+1.7%↑

NVS

150.37

+1.43%↑

MRK

117.85

-1.53%↓

LLY

885.52

+0.86%↑

JNJ

242.36

+0.87%↑

ABBV

213.25

+1.7%↑

NVS

150.37

+1.43%↑

MRK

117.85

-1.53%↓

LLY

885.52

+0.86%↑

JNJ

242.36

+0.87%↑

ABBV

213.25

+1.7%↑

NVS

150.37

+1.43%↑

MRK

117.85

-1.53%↓

LLY

885.52

+0.86%↑

JNJ

242.36

+0.87%↑

ABBV

213.25

+1.7%↑

NVS

150.37

+1.43%↑

MRK

117.85

-1.53%↓

Начало・Списък с акции・Vaxart Inc

Vaxart Inc

Отворен

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

Ключови измерители
By Trading Economics
Приходи	63M 55M
Продажби	32M 104M
P/E Средно за сектора	10.286 57.05
EPS	0.24
Марж на печалбата	52.807
Служители	65
EBITDA	63M 58M

Дивиденти
By Dow Jones
Следващи печалби	12.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-19M 173M
Предишно отваряне	0
Предишно затваряне	0

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

0.4007 / 0.4252 Подкрепа & съпротива

Vaxart Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.03.2026 г., 17:33 ч. UTC

Значими събития в новините

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27.03.2026 г., 17:00 ч. UTC

Значими събития в новините

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27.03.2026 г., 16:03 ч. UTC

Значими събития в новините

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

29.03.2026 г., 23:47 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Falls Amid Rising Inflation Fears -- Market Talk

29.03.2026 г., 23:46 ч. UTC

Пазарно говорене

Значими събития в новините

Nikkei May Fall on Fears About Shortage of Petrochemical Products -- Market Talk

29.03.2026 г., 23:35 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Rises on Supply-Disruption Concerns Spurred by Widening Mideast Conflict -- Market Talk

29.03.2026 г., 23:23 ч. UTC

Пазарно говорене

Australia's National Cabinet to Avoid Covid-Style Measures -- Market Talk

29.03.2026 г., 22:34 ч. UTC

Пазарно говорене

Macroeconomic Tailwind for Warehouse Dissipates -- Market Talk

29.03.2026 г., 22:09 ч. UTC

Пазарно говорене

Amplitude's Next Well "Effectively a Must-Win" for Growth Thesis -- Market Talk

29.03.2026 г., 21:06 ч. UTC

Пазарно говорене

Значими събития в новините

Australia's Economy Could Already Be Contracting Amid Oil Shock -- Market Talk

29.03.2026 г., 21:03 ч. UTC

Пазарно говорене

Australia's Government Wants to Avoid Heavy Handed Oil Shock Response -- Market Talk

29.03.2026 г., 21:01 ч. UTC

Пазарно говорене

Значими събития в новините

Australian National Cabinet Meeting to Focus on Oil Supply -- Market Talk

29.03.2026 г., 09:30 ч. UTC

Придобивния, сливания и поглъщания

Food Mega-Mergers Hardly Ever Work. Could McCormick-Unilever Be Different? -- Heard on the Street -- WSJ

28.03.2026 г., 08:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

27.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

27.03.2026 г., 19:16 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27.03.2026 г., 19:07 ч. UTC

Пазарно говорене

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27.03.2026 г., 19:04 ч. UTC

Пазарно говорене

Gold Rises But Can't Finish the Week Positive -- Market Talk

27.03.2026 г., 19:03 ч. UTC

Пазарно говорене

Значими събития в новините

Global Forex and Fixed Income Roundup: Market Talk

27.03.2026 г., 19:02 ч. UTC

Пазарно говорене

Значими събития в новините

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27.03.2026 г., 18:12 ч. UTC

Пазарно говорене

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27.03.2026 г., 17:36 ч. UTC

Значими събития в новините

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27.03.2026 г., 17:34 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27.03.2026 г., 17:29 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27.03.2026 г., 16:38 ч. UTC

Пазарно говорене

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27.03.2026 г., 16:32 ч. UTC

Пазарно говорене

Значими събития в новините

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27.03.2026 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

27.03.2026 г., 15:43 ч. UTC

Пазарно говорене

Значими събития в новините

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27.03.2026 г., 15:25 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.03.2026 г., 15:25 ч. UTC

Пазарно говорене

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Vaxart Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Vaxart Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.4007 / 0.4252Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.